The linked FDA records identify Caris Life Sciences, at 4610 South 44th Place, Phoenix, AZ 85040, as the applicant on PMA P240010 for MI Cancer Seek, filed April 1, 2024 and approved November 5, 2024. The device is described as a next-generation sequencing based in vitro diagnostic using total nucleic acid isolated from formalin-fixed paraffin-embedded tumor tissue. The collection snapshot retrieved on November 20, 2026 contains two linked PMA records, both with approval decisions, and the smaller record sample likewise shows two approvals. [2][3][7]
The approved device and its stated scope
The approval order describes MI Cancer Seek as detecting single nucleotide variants and insertions and deletions in 228 genes, microsatellite instability, tumor mutational burden in patients with previously diagnosed solid tumors, and copy number amplification in one gene. The Summary of Safety and Effectiveness Data gives the same generic device name and product code PQP, and lists no panel recommendation. [2][3]
Caris Life Sciences states on its own product page that MI Cancer Seek is a simultaneous whole exome sequencing and whole transcriptome sequencing-based assay with FDA-approved companion diagnostic indications for molecular profiling of solid tumors. That characterization is the company's; the FDA records supplied here describe the device in next-generation sequencing terms without using the whole exome and whole transcriptome wording. [4][6]
Filing history in the linked FDA records
The original PMA was received April 1, 2024, amended August 5, 2024, and approved November 5, 2024, according to the FDA approval letter addressed to Peggy Carter, Ph.D., RAC, Corporate Vice President, Regulatory, at Caris Life Sciences. The letter carries docket number 24M-5719 in the device record and notes that class III devices are subject to certain provisions of the unique device identification rule. [2][7]
Supplement S007 was received November 26, 2025 and approved October 16, 2026 under the real-time process supplement type, with the stated reason change design/components/specifications/material. Its approval statement covers migration of the MI Cancer Seek bioinformatics pipeline from an on-premises high-performance computing cluster to Amazon Web Services cloud infrastructure. [1]
How to read the collection counts
The portfolio snapshot reports two linked records, both on the PMA pathway and both approved, and the record sample of two entries shows the same two approvals. These figures describe the supplied filings as of the snapshot date; they are not measures of total company sales, total portfolio or safety performance. [1][2]
No recall records appear in the supplied sample, and the sources include no establishment inspection or adverse-event data for this applicant. The FDA companion diagnostic list page appears among the sources but its supplied excerpt does not name MI Cancer Seek. [8]
Identity and attribution boundaries
The Phoenix address appears in the FDA filing records as the applicant's address; the public documents do not establish a corporate headquarters, parent company, brand structure or commercial availability beyond the applicant name and product names. Statements about the assay's positioning come from Caris Life Sciences' own pages and should be attributed there. [3][4][6]
The company page states that MI Cancer Seek does not report tumor mutational burden for values lower than 3 mut/Mb because accuracy at those values is unreliable, and that treatment decisions rest on the treating physician's independent medical judgment. Those are the publisher's statements, reproduced here as scope information rather than guidance. [6]


